27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our results demonstrate that the multi-modal classifier achieved strong classification performance (accuracy = 68.64%; precision = 73.97%; F1-score=74.48%), with the highest recall (76.39%) from a model incorporating demographics and driving features, and prediction performance (accuracy = 70.48%; precision = 71.88%; F1-score = 74.80%, recall = 77.97%). 1 key finding →
Participants: 118 Evidence: low
Full summary, score breakdown and related studies → Original source
Test-retest reliability measures are essential for interpretation of meaningful effects over time for plasma and digital outcomes. 1 key finding →
Participants: 92 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The global burden of dementia is heavily concentrated in low- and middle-income countries (LMICs), yet biological diagnosis of Alzheimer’s Disease (AD) relies on positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis that are operationally inaccessible in these regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although smartphone usage time is not directly associated with ikigai in older adults, it may reflect preserved physical and cognitive abilities required to navigate digital environments. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
This study provides quantitative evidence supporting the complementary use of multiple cognitive assessment tools. 4 key findings →
Design: cross-sectional Participants: 250 Evidence: low
Full summary, score breakdown and related studies → Original source
Ignite is a sensitive digital cognitive assessment capable of detecting early cognitive changes in genetic FTD and demonstrates improved discrimination compared with standard neuropsychological measures at milder disease severity. 5 key findings →
Participants: 190 Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive impairment is a prevalent symptom extending from physiological ageing to disease. 4 key findings →
Participants: 43 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings support mApp-FTT validity as a measure of motor function across neurodegenerative conditions. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
White matter microstructural abnormalities are increasingly found to be associated with cognitive impairment in Alzheimer’s Disease (AD). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The rs28834970 regulatory variant was identified as the most functionally relevant in our model, with the C risk allele promoting transcription factor C/EBPβ binding within a cis-regulatory element. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
EA ameliorated cognitive impairment in APP/PS1 mice by enhancing TREM2⁺ microglia-mediated Aβ clearance and suppressing neuroinflammation. scRNA-seq further revealed that EA reshaped microglial transcriptional states and intercellular communication networks in a TREM2-dependent manner. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is a risk factor for Alzheimer’s disease (AD), and both conditions are associated with impaired glucose metabolism and mitochondrial dysfunction. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) pathology develops years in advance prior to its clinical presentation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder, and early diagnosis is essential for timely intervention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Electroencephalography (EEG) records cortical activity with high temporal resolution without radiation and at low cost, which makes it a practical signal for automated screening of neurological disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Artificial intelligence (AI) is now a credible translational research platform across the Alzheimer’s disease (AD) pathway, but its clinical value is often difficult to judge from performance metrics alone. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We trained a self-configuring nnU-Net model for CMB segmentation in a hetero-geneous multicenter sample ( n =264), including 1.5T and 3T field strengths, SWI and T2*-GRE sequences, and community and clinical cohorts. 1 key finding →
Participants: 264 Evidence: low
Full summary, score breakdown and related studies → Original source
A bstract INTRODUCTION Treatment response in Alzheimer’s disease (AD) varies substantially across patients, yet no validated frameworks exist to estimate heterogeneous treatment effects (HTE) from observational data while controlling for confounding bias. 2 key findings →
Participants: 4,049 Evidence: low
Full summary, score breakdown and related studies → Original source
EcoXAI replaces monolithic AI text interfaces with an autonomous execution-driven framework with specialized bioinformatics agents for delivering proactive, data-driven insights grounded in established biological knowledge. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Older adults in senior living communities (SLCs) often face barriers to maintaining emotional well-being and family ties. 4 key findings →
Design: randomized controlled trial Participants: 90 Evidence: high
Full summary, score breakdown and related studies → Original source
Early, scalable detection of Alzheimer's disease (AD) and mild cognitive impairment (MCI) remains a global health priority, but non-invasive biomarkers that capture network-level dysfunction during standardized cognitive challenge remain limited. 1 key finding →
Participants: 13 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Wearable devices repeatedly measure activity, sleep, and nocturnal physiology, but their value for three-class cognitive screening remains uncertain. 1 key finding →
Participants: 174 Evidence: low
Full summary, score breakdown and related studies → Original source
Sleeping more than one’s usual average the night before testing was associated with better delayed memory ( β = 0.03, p = 0.02), while no between-person sleep effects emerged. 5 key findings →
Design: cross-sectional Participants: 329 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age-related hearing loss (ARHL) is a main acquired risk factor for dementia, including Alzheimer disease (AD), but links are unknown. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
MedCAT Comorbidity demonstrated predictive ability for mortality (HR 1.11 per condition), although the model fit was better using comorbidity from hospital admission data. 4 key findings →
Participants: 3,543 Evidence: moderate
Full summary, score breakdown and related studies → Original source
8 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →